Whittier Trust Co. Reduces Stake in IQVIA Holdings Inc. $IQV

Whittier Trust Co. reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 40.0% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 10,062 shares of the medical research company’s stock after selling 6,721 shares during the period. Whittier Trust Co.’s holdings in IQVIA were worth $1,718,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the stock. Ameliora Wealth Management Ltd. purchased a new position in IQVIA in the fourth quarter valued at approximately $25,000. International Assets Investment Management LLC purchased a new stake in IQVIA in the fourth quarter worth $27,000. Gilpin Wealth Management LLC bought a new stake in shares of IQVIA in the fourth quarter valued at $27,000. CrossGen Wealth LLC purchased a new position in shares of IQVIA during the 4th quarter valued at $28,000. Finally, Activest Wealth Management grew its stake in shares of IQVIA by 590.0% during the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after acquiring an additional 118 shares during the period. Institutional investors own 89.62% of the company’s stock.

Get IQVIA alerts:

IQVIA Price Performance

IQVIA stock opened at $208.43 on Wednesday. The stock has a market cap of $34.79 billion, a price-to-earnings ratio of 25.83, a PEG ratio of 1.77 and a beta of 1.20. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The business has a 50-day simple moving average of $178.78 and a 200 day simple moving average of $188.85. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $247.04.

IQVIA (NYSE:IQV – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter last year, the firm posted $2.70 EPS. The company’s revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, research analysts forecast that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA announced that its board has initiated a share repurchase program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its stock is undervalued.

Analyst Upgrades and Downgrades

IQV has been the subject of several recent research reports. Weiss Ratings lowered IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Evercore reiterated an “outperform” rating and set a $185.00 target price on shares of IQVIA in a research report on Wednesday, April 8th. Robert W. Baird lifted their target price on shares of IQVIA from $230.00 to $249.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 1st. Morgan Stanley restated an “equal weight” rating and set a $200.00 price target (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Finally, HSBC reaffirmed a “buy” rating and issued a $240.00 price objective on shares of IQVIA in a report on Monday. Fourteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average target price of $223.88.

Check Out Our Latest Research Report on IQVIA

IQVIA Profile

(Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Further Reading

• Five stocks we like better than IQVIA
• Apple and Broadcom Forge a Decade-Long Silicon Fortress
• SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
• The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
• Palantir’s CEO Just Called Out OpenAI and Anthropic

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.